search
Back to results

Exparel for Pain Control During Care of Rib Fractures

Primary Purpose

Pain

Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
EXPAREL
Sponsored by
Michael Moncure, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain focused on measuring Pain management, Exparel, Rib fracture

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients 18 years of age or older
  • patients with three or more rib fractures occurring either unilaterally or bilaterally
  • patients who are awake enough to assess pain severity

Exclusion Criteria:

  • patients whose pain in other anatomical areas limit rib fracture pain assessment
  • patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioids, or ketorolac
  • patients who abuse alcohol or other drug substances
  • patients on chronic opioid therapy (taken an opioid 5 of the last 7 days)
  • pregnant patients
  • severe hepatic impairment
  • persistent pain patients requiring 20mg oral morphine equivalent or greater in the 24 hour period prior to sustaining multiple rib fractures
  • allergies to common agents used in Exparel (bupivacaine, liposome)
  • inability to provide informed consent

Sites / Locations

  • University of Kansas Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EXPAREL

Arm Description

single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture

Outcomes

Primary Outcome Measures

Pain relief (visual analog scale)
pain relief as measured by visual analog scale and patient satisfaction survey, before and after drug administration

Secondary Outcome Measures

Length of hospital stay post treatment
count of days participant in hospital post treatment
opioid use
change in lung function as evidenced by use of incentive spirometry
Changes will be measured by using incentive spirometry. The incentive spirometry device includes an indicator which measures sustained inhalation vacuum. Change between performance will be measured at treatment to hour 72.

Full Information

First Posted
March 3, 2015
Last Updated
January 17, 2017
Sponsor
Michael Moncure, MD
search

1. Study Identification

Unique Protocol Identification Number
NCT02390440
Brief Title
Exparel for Pain Control During Care of Rib Fractures
Official Title
Liposomal Bupivicaine (Exparel) for Pain Control During Care of Rib Fractures
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Withdrawn
Why Stopped
Did not obtain an IND.
Study Start Date
April 2015 (undefined)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
January 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Michael Moncure, MD

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is looking at a novel therapy of numbing medication injected directly around the fracture site. The purpose of this study is to determine if the study medication, EXPAREL®, is a viable alternative to current therapies for rib fractures.
Detailed Description
Rib fractures are common in patients who have suffered a traumatic injury, occurring in about 10% of general injury cases and in about 30% of cases where the injury is directly to the chest. Usually caused by injury to the chest wall, rib fractures most often occur where the ribs bend and are most fragile. These kinds of injuries are commonly caused by motor vehicle collisions, falls, assault, industrial accidents, gunshots, or repetitive causes such as severe coughing or use-injury in athletes. With any of these types of injury, the first concern of the physician is to repair any immediate damage to the chest wall (such as penetrating wounds, air or blood in the chest cavity that compresses the lung(s), or fixing the broken ribs in place). Once these injuries are repaired and stabilized, the patient's care consists of controlling their pain and helping them recover normal breathing ability. In patients who are not admitted to the hospital for care, usually with only 1 or 2 ribs broken, care is often pain control using over the counter medicines like Tylenol or Ibuprofen (called NSAIDS) or prescription medicines like hydrocodone (Vicodin®). The main concern during follow-up of these patients is full recovery of pain-free breathing ability. In patients who are admitted to the hospital for treatment, pneumonia is the most common complication associated with multiple broken ribs. Pneumonia occurs in anywhere from 15% to 30% of these patients. For long-acting pain control to help them breathe more easily, studies have shown that epidural analgesia (pain relieving drugs delivered through a thin tube called a catheter into the fluid surrounding the spinal cord) is preferable over opioids, whether given in pill form or through an IV. Additional studies have shown better results with epidural pain control compared to opioid or NSAID use. However, with all of these methods come risks and side effects. Using oral NSAIDs can result in stomach irritation, kidney injury, or can interfere with the body's ability to form blood clots. Acetaminophen (Tylenol) has been shown to be toxic to the liver at higher doses. Opioid use can lower a person's breathing ability even while it reduces their pain, which is not wanted in patients already at higher risk for pneumonia. Epidural placement is a complex procedure, risks infection at the site of catheter insertion, can cause itching, and risks injury to both the spinal cord and the membrane surrounding it (the dura).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain
Keywords
Pain management, Exparel, Rib fracture

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EXPAREL
Arm Type
Experimental
Arm Description
single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture
Intervention Type
Drug
Intervention Name(s)
EXPAREL
Other Intervention Name(s)
Liposomal Bupivicaine
Primary Outcome Measure Information:
Title
Pain relief (visual analog scale)
Description
pain relief as measured by visual analog scale and patient satisfaction survey, before and after drug administration
Time Frame
Change from Treatment to Hour 72
Secondary Outcome Measure Information:
Title
Length of hospital stay post treatment
Description
count of days participant in hospital post treatment
Time Frame
Up to 10 days, average length of stay expected to be 3 days
Title
opioid use
Time Frame
Change from Treatment to Hour 72
Title
change in lung function as evidenced by use of incentive spirometry
Description
Changes will be measured by using incentive spirometry. The incentive spirometry device includes an indicator which measures sustained inhalation vacuum. Change between performance will be measured at treatment to hour 72.
Time Frame
Change from Treatment to Hour 72

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients 18 years of age or older patients with three or more rib fractures occurring either unilaterally or bilaterally patients who are awake enough to assess pain severity Exclusion Criteria: patients whose pain in other anatomical areas limit rib fracture pain assessment patients with a history of hypersensitivity or idiosyncratic reactions or intolerance to any local anesthetic, opioids, or ketorolac patients who abuse alcohol or other drug substances patients on chronic opioid therapy (taken an opioid 5 of the last 7 days) pregnant patients severe hepatic impairment persistent pain patients requiring 20mg oral morphine equivalent or greater in the 24 hour period prior to sustaining multiple rib fractures allergies to common agents used in Exparel (bupivacaine, liposome) inability to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Moncure, MD, FACS
Organizational Affiliation
University of Kansas Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Exparel for Pain Control During Care of Rib Fractures

We'll reach out to this number within 24 hrs